Inivata Limited, a Cambridge, UK-based clinical cancer genomics company employing the precision of circulating tumour DNA analysis to improve personalized healthcare in oncology, completed a £31.5M Series A funding. (approx. $45M).
Backers included existing investors Imperial Innovations, Cambridge Innovation Capital, and Johnson & Johnson Innovation – JJDC, Inc. and new investor Woodford Patient Capital Trust.
The company intends to use the funds to accelerate clinical studies to validate its technology platform based on enhanced TAm-Seq, and commercialize their first products.
Led by Michael Stocum, Chief Executive Officer, Inivata provides a platform which will initially be applied across a spectrum of solid tumors, including lung, breast and colon cancer to demonstrate the integration of genomic information with clinically actionable decision-making.
The company’s proprietary technology represents a new generation of non-invasive molecular profiling from a simple blood draw that can impact the major aspects of a patient’s care including diagnosis, prognosis, treatment stratification and response monitoring.
The test, which allows precise analysis of cancer-related mutations present in ctDNA, is designed to provide oncologists with clinically actionable genomic information to guide therapy selection, monitor treatment progress and, detect new mutations as they emerge.
Inivata’s platform is based on research from the Rosenfeld Lab at the Cancer Research UK Cambridge Institute (CRUK-CI).